default author photo

Alon Peretz

Clalit Health Services - Community Medical Services Division

Tel Aviv

Israel

  • Clalit Health Services - Community Medical Services Division

SCHOLARLY PAPERS

4

DOWNLOADS

6,117

TOTAL CITATIONS

0

Scholarly Papers (4)

Actions:
Email selected abstracts
1.

Effectiveness of the Bivalent mRNA Vaccine in Preventing Severe COVID-19 Outcomes: An Observational Cohort Study

Number of pages: 17 Posted: 03 Jan 2023
Ronen Arbel, Alon Peretz, Ruslan Sergienko, Michael Friger, Tanya Beckenstein, Shlomit Yaron, Ariel Hammerman, Natalya Bilenko and Doron Netzer
Clalit Health Services - Community Medical Services Division, Clalit Health Services - Community Medical Services Division, Ben-Gurion University of the Negev - Faculty of Health Science, Ben-Gurion University of the Negev - Faculty of Health Science, Clalit Health Services - Community Medical Services Division, Clalit Health Services - Community Medical Services Division, Clalit Health Services - Community Medical Services Division, Ben-Gurion University of the Negev - Faculty of Health Science and Clalit Health Services - Community Medical Services Division
Downloads 5,697

Abstract:

Loading...

COVID-19, Bivalent booster vaccine

2.

Safety of COVID-19 Monovalent and Bivalent BNT162b2 mRNA Vaccine Boosters for Adults 60 Years and Above: A Large-Scale Retrospective Study

Number of pages: 43 Posted: 25 Jan 2023
Dan Yamin, Matan Yechezkel, Ronen Arbel, Tanya Beckenstein, Ruslan Sergienko, Hadar Duskin-Bitan, Shlomit Yaron, Alon Peretz, Doron Netzer and Erez Shmueli
Tel Aviv University - Department of Industrial Engineering, Tel Aviv University - Laboratory for Epidemic Modeling and Analysis, Clalit Health Services - Community Medical Services Division, Clalit Health Services - Community Medical Services Division, Ben-Gurion University of the Negev - Department of Health Policy and Management, Clalit Health Services - Community Medical Services Division, Clalit Health Services - Community Medical Services Division, Clalit Health Services - Community Medical Services Division, Clalit Health Services - Community Medical Services Division and Tel Aviv University - Department of Industrial Engineering
Downloads 190

Abstract:

Loading...

COVID-19 vaccine, COVID-19 booster vaccine, BNT162b2, adverse events, bivalent vaccine, vaccine safety, cardiovascular disease, ischemic stroke

3.

Second Booster Vaccine Dose for Older Adults and COVID-19 Mortality During the Omicron Surge

Number of pages: 23 Posted: 25 Mar 2022
Ronen Arbel, Ruslan Sergienko, Michael Friger, Alon Peretz, Tanya Beckenstein, Shlomit Yaron, Doron Netzer and Ariel Hammerman
Clalit Health Services - Community Medical Services Division, Ben-Gurion University of the Negev - Faculty of Health Science, Ben-Gurion University of the Negev - Faculty of Health Science, Clalit Health Services - Community Medical Services Division, Clalit Health Services - Community Medical Services Division, Clalit Health Services - Community Medical Services Division, Clalit Health Services - Community Medical Services Division and Clalit Health Services - Community Medical Services Division
Downloads 153

Abstract:

Loading...

4.

Effectiveness of REGEN-COV Antibody Combination in Preventing Severe COVID-19 Outcomes – A Retrospective Cohort Study ​

Number of pages: 17 Posted: 24 Jan 2022
Samah Hayek, Yatir Ben Shlomo, Noa Dagan, Ben Y. Reis, Noam Barda, Eldad Kepten, Alina Roitman, Shachar Shapira, Shlomit Yaron, Ran Balicer, Doron Netzer and Alon Peretz
Clalit Health Services, Clalit Health Services, Clalit Health Services, Harvard University - Harvard Medical School, Clalit Health Services, Clalit Health Services, Clalit Health Services, Israel Defense Forces (IDF), Clalit Health Services - Community Medical Services Division, Ben Gurion University of the Negev, Clalit Health Services - Community Medical Services Division and Clalit Health Services - Community Medical Services Division
Downloads 77

Abstract:

Loading...

COVID-19 infection, SARS-CoV-2, REGEN-COV treatment, COVID-19 treatment, observational studies, treatment effectiveness, two SARS-CoV-2 antibodies (Casirivimab and Imdevimab)